Beyond Air to Participate in the D. Boral Capital Global Conference 2026
Rhea-AI Summary
Beyond Air (NASDAQ: XAIR) announced that CEO Robert Goodman and CFO Dan Moorhead will participate in the D. Boral Capital Global Conference 2026 on May 7, 2026 at The Plaza Hotel in New York.
The company will hold one-on-one meetings with investors; interested parties should contact their D. Boral Capital representative to request scheduling.
Positive
- None.
Negative
- None.
News Market Reaction – XAIR
In the Apr 15 session, XAIR declined 11.58%, reflecting a significant negative market reaction. Argus tracked a peak move of +27.5% during that session. Argus tracked a trough of -20.7% from its starting point during tracking. Our momentum scanner triggered 32 alerts that day, indicating elevated trading interest and price volatility. Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 01 | Commercial agreement | Positive | +3.5% | National GPO deal expanding LungFit PH access to nearly 2,000 hospitals. |
| Mar 26 | Leadership change | Neutral | +0.2% | CEO transition from Steve Lisi to Robert Goodman to lead commercialization. |
| Mar 17 | Clinical update | Positive | +0.3% | Interim Phase 1 UNO data showing early activity and favorable safety profile. |
| Mar 11 | Conference participation | Neutral | -2.6% | Announcement of participation in the 38th Annual Roth investor conference. |
| Mar 10 | Deal termination | Neutral | -4.0% | Termination of planned NeuroNOS sale while retaining and reassessing the asset. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has produced mixed reactions: commercial and clinical positives generally aligned with modest gains, while neutral corporate updates have sometimes coincided with downside moves.
Over the last few months, XAIR reported stronger fiscal Q3 revenue of $2.2 million with narrowed losses and expanding LungFit PH adoption. It secured a national GPO agreement expanding access to nearly 2,000 hospitals and reported encouraging Phase 1 UNO data with early clinical activity. Corporate actions included a CEO transition to Robert Goodman and termination of the planned NeuroNOS sale. Today’s conference participation follows earlier investor outreach at the Roth Conference, continuing a pattern of active engagement alongside operational updates.
Key Terms
nitric oxide medical
nasdaq financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
GARDEN CITY, N.Y., April 15, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients’ lives, today announced that Robert Goodman, Chief Executive Officer, and Dan Moorhead, Chief Financial Officer of Beyond Air, will participate in the D. Boral Capital Global Conference 2026, which is being held on Thursday, May 7th, at The Plaza Hotel in New York.
| Conference | ||
| Format: | One-on-one meetings | |
| Conference Dates: | May 7th | |
| Participants: | Robert Goodman, CEO, and Dan Moorhead, CFO of Beyond Air | |
If you are interested in requesting a one-on-one meeting at the conference, please contact your D. Boral Capital representative to schedule accordingly.
About Beyond Air, Inc.
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. For more information, visit www.beyondair.net.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the Company’s expectations related to the commercial growth, market adoption of LungFit PH, expansion in the U.S. and international markets, and the Company’s long-term strategic and financial performance. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “plan,” “potential,” “will,” “would,” “could,” “may,” and similar expressions, or by the use of future tense. These statements are based on current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management.
Because forward-looking statements relate to future events, they are subject to inherent risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks related to the Company’s ability to successfully execute its commercial strategy, achieve market adoption of its products, maintain and expand customer relationships, manage leadership transitions effectively, obtain additional financing, and other risks described in the “Risk Factors” section of Beyond Air, Inc.’s most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission.
CONTACTS:
Investor Relations contact
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
(212) 915-2577
